Fragmin ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
222一次性ネフローゼ症候群1

222. 一次性ネフローゼ症候群


臨床試験数 : 310 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-001212-29-DK
(EUCTR)
26/08/202009/06/2020Causes and prevention of thrombosis developed due to the kidney disease nephrotic syndromeCauses and Prevention of Thromboembolic Disease in Nephrotic Syndrome Nephrotic syndrome is defined as severe proteinuria (> 0.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of a large number of plasma proteins including coagulation factors and consequently a increased risk of thromboembolic complications. The most frequent cause of nephrotic syndrome is the renal disease membranous nephropathy, which is associated with the greatest risk of thromboembolic complications.
MedDRA version: 21.1;Level: LLT;Classification code 10029167;Term: Nephrotic syndrome with lesion of membranous glomerulonephritis;System Organ Class: 100000004857
MedDRA version: 20.0;Classification code 10029165;Term: Nephrotic syndrome in diseases classified elsewhere;System Organ Class: 100000004857;Therapeutic area: Not possible to specify
Trade Name: Fragmin
INN or Proposed INN: Dalteparin
Other descriptive name: Dalteparin
Trade Name: Eliquis
INN or Proposed INN: Apixaban
Other descriptive name: Apixaban
Aarhus University Hospital, Henrik BirnNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 1;Phase 2Denmark